DA 2803
Alternative Names: DA-2803Latest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Dong-A ST
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in South Korea (PO, Tablet)
- 02 Jun 2021 Dong-A ST plans a phase I trial in Hepatitis B (In volunteers) in South Korea (PO, Tablet), in June 2021 (NCT04906109)
- 28 May 2021 Preclinical trials in Hepatitis B in South Korea (PO), prior to May 2021